Drugs / Alveavax-v1.2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05844202 | Jun 2022 → Mar 2023 | COVID-19 | Alvea Holdings, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alveavax-v1.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844202 ↗ |
| Modality | Vaccine | “BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19” NCT05844202 ↗ |
| Route | Subcutaneous | “intradermal (ID) and subcutaneous (SC) application” NCT05844202 ↗ |